CliffBio
small molecule

ERIBULIN MESYLATE

ERIBULIN MESYLATE

Loss of exclusivity—loss of exclusivity
CompanyLong Grove →See this company's full patent-cliff portfolio

Drug detail

Brand nameERIBULIN MESYLATE
Active ingredientERIBULIN MESYLATE
Strength1MG/2ML (0.5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2024
Marketing statusRX

More from Long Grove

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.